Founded Entities
PureTech's Founded Entities are advancing 20 therapeutics and therapeutic candidates, of which two have been cleared for marketing by the U.S. FDA and granted marketing authorization in the European Economic Area and a third that will soon be filed for FDA approval, and 13 are clinical stage.
All of these underlying programs and platforms across PureTech's Founded Entities were initially identified or discovered and then advanced by its team through key validation points before being further developed by each respective Founded Entity.

Founded Entities
$3.1B
Investments and Non-Dilutive Funding Raised by Founded Entities Since January 2018 through August 20222
Advancing transformative medicines for people living with psychiatric and neurological conditions
Schizophrenia
~2.7M U.S.
Alzheimer’s disease psychosis
~3.2M U.S.
Pioneering the development of cognitive treatments through game-changing technologies
Pediatric ADHD 8-12 y/o (U.S.)
~1.8M U.S.
Cognitive dysfunction in MDD
~2.1M U.S.
Cognitive dysfunction in MS
~180K U.S.
Attention in ASD
~410K U.S.
Post-COVID acute cognitive dysfunction
~1.3M U.S.
Post-ICU acute cognitive dysfunction
~300K U.S.
Cancer-related acute cognitive dysfunction
~1M U.S.
Pediatric ADHD 13-17 y/o (U.S.)
Adult ADHD 18+ y/o (U.S.)
Advancing a novel category of treatments for weight management and gut related chronic diseases
Weight management
~150M U.S. (Overweight and obesity)
For adolescents6
Adolescent weight management
~13.7M U.S.
Weight management in type 2 diabetes (T2D)/prediabetes
~32M U.S. (T2D)
~88M U.S. (Prediabetes)
Non-alcoholic steatohepatitis/Non-alcoholic fatty liver disease
~80-100M U.S.
Functional constipation
~35M U.S.
Engineering hematopoietic stem cells to enable targeted therapies post-transplant
Acute myeloid leukemia
~42,500/year U.S., Europe, Japan
Pioneering a new category of oral therapies based on defined bacterial consortia
Clostridioides difficile
~100-120K/year U.S.
Inflammatory bowel disease
~3M U.S.
Food allergy
~2.5M U.S. (Peanut allergy)
Solid tumors
>46K/year U.S. (Advanced & metastatic MSS CRC)
>11K/year U.S. (Gastric cancers)
>9K/year U.S. (Melanoma)
Building a regenerative biology platform for androgenetic alopecia, epithelial aging and other medical indications
Androgenetic alopecia
~90M U.S.
Developing a voice-based technology platform to detect changes of health conditions
Monitoring vocal features linked to depression, anxiety and cognition
~17M U.S.
Engineering hydrogels to enable the oral administration of biologics
2 Funding figure can include private equity financings, loans and promissory notes, public offerings or grant awards, and gross proceeds from SPAC mergers. Funding figure excludes future milestone considerations received in conjunction with partnerships and collaborations.
3 EndeavorRx® is a digital therapeutic indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure, Test of Variables of Attention (TOVA®), of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder. There were no serious adverse events; 9.3% of subjects experienced side effects, including frustration, headache, dizziness, emotional reaction, nausea or aggression. EndeavorRx is only available to your patients through a prescription, and is not intended as a stand-alone therapeutic or a substitute for your patient’s medication.
4 Multiple IRBs have determined AKL-T01 to be a non-significant risk device. Akili has obtained IRB approval independently or in collaboration with independent clinical research institutions for all past and ongoing human data collection for clinical research in the United States. We do not control the clinical or regulatory development of Akili’s product candidates. We do not have a direct interest in Akili’s therapeutic or therapeutic candidates. Our interest in Akili’s therapeutic and therapeutic candidates is limited to our equity interest in Akili and any potential appreciation in the value of such equity interest, and we do not control the clinical or regulatory development of Akili’s therapeutic candidates. Akili is well-protected with a robust intellectual property portfolio. Akili was incorporated in February 2012.
5 Important Safety Information about Plenity®: Patients who are pregnant or are allergic to cellulose, citric acid, sodium stearyl fumarate, gelatin, or titanium dioxide should not take Plenity. To avoid impact on the absorption of medications: For all medications that should be taken with food, take them after starting a meal. For all medications that should be taken without food (on an empty stomach), continue taking on an empty stomach or as recommended by your physician. The overall incidence of side effects with Plenity was no different than placebo. The most common side effects were diarrhea, distended abdomen, infrequent bowel movements, and flatulence. Contact a doctor right away if problems occur. If you have a severe allergic reaction, severe stomach pain, or severe diarrhea, stop using Plenity until you can speak to your doctor. Rx Only. For the safe and proper use of Plenity or more information, talk to a healthcare professional, read the Patient Instructions for Use, or call 1-844-PLENITY.
6 These therapeutic candidates are regulated as devices and their development has been approximately equated to phases of clinical development.
7 Contingent on FDA review of the research plan.
Developing breakthrough medicines at PureTech

